Who
Francis Burrows
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Kura Oncology.
In numbers
- Trades disclosed
- 16
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $720K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 2 Jan 2025
- Last trade
- 24 Sep 2026
- Last filed
- 25 Sep 2026
Companies traded
Activity over time
1 Jan 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Sep 2026filed 25 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code M | $185K30,000 at $6.15 | filing |
| 24 Sep 2026filed 25 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $225K20,726 at $10.83 | filing |
| 24 Sep 2026filed 25 Sep 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —30,000 at $0.00 | filing |
| 24 Sep 2026filed 25 Sep 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —30,000 at $0.00 | filing |
| 24 Sep 2026filed 25 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code M | $185K30,000 at $6.15 | filing |
| 24 Sep 2026filed 25 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $224K20,726 at $10.83 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $11K1,311 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $11K1,311 at $8.46 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —185,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —185,000 at $0.00 | filing |
| 18 Dec 2025filed 19 Dec 2025 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —35,000 at $0.00 | filing |
| 18 Dec 2025filed 19 Dec 2025 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code M | $168K35,000 at $4.80 | filing |
| 18 Dec 2025filed 19 Dec 2025 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $232K23,726 at $9.78 | filing |
| 28 Jan 2025filed 28 Jan 2025 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $6,658846 at $7.87 | filing |
| 28 Jan 2025filed 28 Jan 2025 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $10K1,320 at $7.87 | filing |
| 2 Jan 2025filed 7 Jan 2025 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —185,000 at $0.00 | filing |
News
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in DiabetesKURA · manilatimes.net · 13 Oct 2026Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in DiabetesKURA · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Francis Burrows; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.